Relmada Therapeutics, Inc.
Edit

Relmada Therapeutics, Inc.

http://www.relmada.com/
Last activity: 27.07.2021
Active
Categories: InformationMedtechProductPublicSpecialty
Developing new products for the treatment of acute and chronic pain.
Exited Portfolio Company
www.relmada.com
Mentions
35
Total raised: $11M
Email

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
01.10.2013Series A$8M-
24.07.2012Series A$3M-

Mentions in press and media 35

DateTitleDescription
27.07.2021Relmada Therapeutics : Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse PotentialNEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HA...
27.07.2021Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
20.07.2021Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSEWith the recent and unexpected discovery of probable human carcinogen impurities prompting recalls of popular heartburn drugs like Zantac and nizatidine, as well as metformin diabetes medicines, ARBs and more, the FDA has made clear the nee...
20.07.2021Gilead still has­n't made up its mind about Ar­cus' drugs, but there's a top ex­ec at the biotech it def­i­nite­ly wantsDavid Risinger spent more than 20 years observing the biopharma scene from the outside, spending the last 12 years at Morgan Stanley and ending as head of equity research on the Big Pharma front. Now, he’s making the leap to go inside biote...
20.07.2021Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSEThere has been a surge in in­vest­ment in psy­che­del­ic biotechs in re­cent years, and Rel­ma­da Ther­a­peu­tics is hop­ping on board. CNS-fo­cused Rel­ma­da will pay a to­tal of $15 mil­lion up­front — a mix of cash and eq­ui­ty pur­chase...
20.07.2021On a mis­sion to sup­port 'un­der­served' Eu­ro­pean star­tups, Panakès Part­ners dips in­to the biotech sec­tor with its lat­est fundDi­ana Saraceni knows how to put to­geth­er a VC fund. Af­ter co-found­ing Italy-based Panakès Part­ners back in 2015, the man­ag­ing part­ner is now clos­ing the sixth fund of her ca­reer — but this time, her firm is dip­ping in­to the bio...
20.07.2021The next SPAC is here, com­ing from a phar­ma e-com­merce CEO, as a Flori­da biotech prices at the low endThe newest health­care blank-check com­pa­ny has ar­rived, com­ing from the CEO of a com­pa­ny that is at­tempt­ing to shake up the dig­i­tal phar­ma­ceu­ti­cal space. The SPAC known as Aes­ther Health­care Ac­qui­si­tion filed for its ini­...
20.07.2021Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC
20.07.2021Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSEAs the US emerges from a yearlong lockdown, the Delta variant — the most contagious strain of the novel coronavirus identified to date — continues to spread rapidly around the world, threatening to derail hopes for a swift economic comeback...
20.07.2021Can a next-gen take on a dead­ly weight loss pill con­quer car­diometa­bol­ic dis­eases? A Medicxi-backed start­up thinks soMost drug de­vel­op­ers might re­mem­ber DNP, the yel­low­ish com­pound that’s been used over the years as a her­bi­cide and chem­i­cal in­ter­me­di­ate, as a dead­ly di­et pill. But Sha­har­yar Khan and Allen Cun­ning­ham won­dered about t...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In